Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher

This late-stage clinical trial company focuses on preventing inflammation and acute organ injury. It is developing a platform of new drugs to prevent inflammation in the kidneys, liver and lungs via the dipeptidase-1 (DPEP1) pathway, addressing common injuries and diseases where organ inflammation remains an unmet need. And now, they are looking at a major breakthrough in treating common injuries and diseases where organ inflammation affects millions of patients globally annually with an LSALT peptide. 

Arch Biopartners Inc. (TSX Venture: ARCH) (OTCQB: ACHFF) announced in a press release today that patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). Acute kidney injury (AKI) is a common complication, with an increased risk in patients undergoing coronary artery bypass grafting (CABG) and other on-pump cardiac surgeries. The reported prevalence of CS-AKI is up to 30 percent, and it is independently associated with higher morbidity and mortality rates.

The CS-AKI Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled study of LSALT peptides with a recruitment target of 240 patients. The trial’s primary objective is to evaluate the percentage of subjects with acute kidney injury (AKI) within seven days following on-pump (heart-lung machine) cardiac surgery, as defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

View the original article on AllPennyStocks.com